Research programme: anti-transforming growth factor beta antibodies- XOMA Corporation/Novartis

Drug Profile

Research programme: anti-transforming growth factor beta antibodies- XOMA Corporation/Novartis

Alternative Names: XOMA-089

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Fibrosis

Highest Development Phases

  • Preclinical Cancer; Fibrosis

Most Recent Events

  • 16 Mar 2017 Xoma has patent protection for anti-TGFβ antibody programme in USA
  • 01 Oct 2015 XOMA Corporation's anti-transforming growth factor beta antibody program licensed to Novartis worldwide
  • 06 Aug 2015 Interim pharmacodynamics data from a preclinical trial in fibrosis released by XOMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top